Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue Gross Profit Leases Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Shares Issued Shares Outstanding Shares Outstanding

Ratios

enVVeno Medical (NVNO) Long-Term Debt Issuances (2017 - 2018)

enVVeno Medical has reported Long-Term Debt Issuances over the past 2 years, most recently at -$1.9 million for Q3 2018.

For Q3 2018, Long-Term Debt Issuances changed N/A year-over-year to -$1.9 million; the TTM value through Dec 2020 reached -$1.9 million, changed N/A, while the annual FY2020 figure was $312700.0, N/A changed from the prior year.
Long-Term Debt Issuances for Q3 2018 was -$1.9 million at enVVeno Medical, down from $2.6 million in the prior quarter.
Over five years, Long-Term Debt Issuances peaked at $5.3 million in Q4 2017 and troughed at -$1.9 million in Q3 2018.